RxDoctor Payments DataLook up a doctor →

Yekaterina Grigol, PA

Medical · Naples, FLNPI 1558734178

Payments from drug & device makers

$17,714in general payments, 2019–2025

Across 830 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Johnson & Johnson$2K
  • UCB, Inc.$2K
  • Novartis$1K
  • AbbVie$1K
  • Lilly USA, LLC$877
  • plus $5K from 25 others

What the payments were for

  • Consulting fees$3002%
  • Food & beverage$16,99696%
  • Education$4182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,714 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$143,082
Medicare patients
386
Services billed
2,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast21$97,499
OrenciaAbatacept14$92,684
Humira(Cf)Adalimumab13$84,226
EnbrelEtanercept11$80,448
Xeljanz XrTofacitinib Citrate11$74,058
TymlosAbaloparatide22$72,530
Hydroxychloroquine Sulfate347$10,388
OtrexupMethotrexate/Pf12$8,757
Prednisone580$6,031
MethotrexateMethotrexate Sodium200$5,560
Colchicine28$3,016
Febuxostat15$2,238
Methylprednisolone90$2,043
Leflunomide16$1,861
Alendronate Sodium183$1,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$5,460$177,94832 claims
E.r. Squibb & Sons, L.L.C.Orencia$394$92,68414 claims
AbbVieHumira(Cf)$1,228$84,22613 claims
Radius Health, Inc.Tymlos$329$72,53022 claims
Scilex Pharmaceuticals Inc.Colchicine$41$3,01628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.

Other medical in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →